



## Clinical trial results:

### Multicenter, Open-Label, Safety, Tolerability, and Pharmacokinetic Study to Evaluate Single Ascending Doses and Subsequent Short-Term Administration of Fixed Doses of Desvenlafaxine Succinate Sustained-Release Tablets in the Treatment of Child and Adolescent Outpatients With Major Depressive Disorder.

#### Summary

EudraCT number	2008-002066-57
Trial protocol	Outside EU/EEA
Global end of trial date	12 November 2009

#### Results information

Result version number	v2 (current)
This version publication date	03 August 2016
First version publication date	31 July 2015
Version creation reason	• Correction of full data set typographical error to be corrected

#### Trial information

##### Trial identification

Sponsor protocol code	3151A6-2000
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00619619
WHO universal trial number (UTN)	-
Other trial identifiers	Alias ID: B2061012

Notes:

#### Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Clinical Trials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Clinical Trials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 April 2012
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 November 2009
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

- 1) To investigate the safety and tolerability of single ascending doses of Desvenlafaxine Sustained Release (DVS SR) in children and adolescents with Major Depressive Disorder (MDD).
- 2) To characterize the Pharmacokinetics (PK) profile of single ascending doses of DVS SR in children and adolescents with MDD.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 59
Worldwide total number of subjects	59
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	29

Adolescents (12-17 years)	30
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Treatment to be given at only 1 dose level at a time for at least the first 6 subjects per dose group. Approximately 6 to 8 subjects were to be enrolled in each of the dose cohorts; 4 dose levels were to be evaluated per age stratum in sequential manner and ascending order (10 to 100 milligrams [mg] for children; 25 to 200 mg for adolescents).

### Pre-assignment

Screening details:

Screening period 6 to 14 days followed by treatment period (up to 3.5 day inpatient and up to 7.5 week outpatient phase). Subjects who enter outpatient period but do not continue 6-month open-label extension study (NCT00669110 [2008-002067-14]) will participate in taper period of 0 to 2 weeks depending on dose of assigned study treatment.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Desvenlafaxine 10 mg Children

Arm description:

Desvenlafaxine sustained release 10 mg tablet.

Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered Desvenlafaxine sustained release 10 mg tablet.

<b>Arm title</b>	Desvenlafaxine 25 mg Children
------------------	-------------------------------

Arm description:

Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.

Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.

<b>Arm title</b>	Desvenlafaxine 50 mg Children
------------------	-------------------------------

Arm description:

Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
<b>Arm title</b>	Desvenlafaxine 100 mg Children
Arm description:	
Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
<b>Arm title</b>	Desvenlafaxine 25 mg Adolescent
Arm description:	
Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
<b>Arm title</b>	Desvenlafaxine 50 mg Adolescent
Arm description:	
Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects were administered Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
<b>Arm title</b>	Desvenlafaxine 100 mg Adolescent

Arm description:

Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.

Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.

<b>Arm title</b>	Desvenlafaxine 200 mg Adolescent
------------------	----------------------------------

Arm description:

Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14.

Arm type	Experimental
Investigational medicinal product name	Desvenlafaxine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14.

<b>Number of subjects in period 1</b>	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children
Started	6	7	9
Entered the Extension Study	6	5 <sup>[1]</sup>	8
Completed	6	7	8
Not completed	0	0	1
Physician decision	-	-	1
Adverse Event	-	-	-
Protocol Violation	-	-	-

<b>Number of subjects in period 1</b>	Desvenlafaxine 100 mg Children	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent
Started	7	7	7
Entered the Extension Study	3 <sup>[2]</sup>	7	6 <sup>[3]</sup>
Completed	6	5	7
Not completed	1	2	0
Physician decision	-	-	-
Adverse Event	-	2	-
Protocol Violation	1	-	-

<b>Number of subjects in period 1</b>	<b>Desvenlafaxine 100 mg Adolescent</b>	<b>Desvenlafaxine 200 mg Adolescent</b>
Started	8	8
Entered the Extension Study	6 <sup>[4]</sup>	7
Completed	7	5
Not completed	1	3
Physician decision	-	-
Adverse Event	-	2
Protocol Violation	1	1

---

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The number of subjects in this milestone represents those subjects who enter the extension study.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The number of subjects in this milestone represents those subjects who enter the extension study.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The number of subjects in this milestone represents those subjects who enter the extension study.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: The number of subjects in this milestone represents those subjects who enter the extension study.

## Baseline characteristics

Reporting groups	
Reporting group title	Desvenlafaxine 10 mg Children
Reporting group description: Desvenlafaxine sustained release 10 mg tablet.	
Reporting group title	Desvenlafaxine 25 mg Children
Reporting group description: Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
Reporting group title	Desvenlafaxine 50 mg Children
Reporting group description: Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 100 mg Children
Reporting group description: Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 25 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
Reporting group title	Desvenlafaxine 50 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 100 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 200 mg Adolescent
Reporting group description: Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14.	

Reporting group values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children
Number of subjects	6	7	9
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	8.33	9.57	9.89
standard deviation	± 1.33	± 1.13	± 1.27
Gender categorical			
Units: Subjects			
Female	4	3	3



Male	2	4	6
------	---	---	---

Children's Depression Ratings Scale-Revised (CDRS-R) total score			
CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms.			
Units: scores on a scale			
arithmetic mean	57.5	52.43	49.89
standard deviation	± 4.89	± 5.13	± 7.3

Reporting group values	Desvenlafaxine 100 mg Children	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent
Number of subjects	7	7	7
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	9.71	15	13.14
standard deviation	± 0.95	± 1.83	± 1.46
Gender categorical			
Units: Subjects			
Female	4	4	3
Male	3	3	4
Children's Depression Ratings Scale-Revised (CDRS-R) total score			
CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms.			
Units: scores on a scale			
arithmetic mean	46.43	64.86	57.71
standard deviation	± 4.35	± 11.87	± 1.98

Reporting group values	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent	Total
Number of subjects	8	8	59
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	14.25	14	
standard deviation	± 1.67	± 1.6	-
Gender categorical			
Units: Subjects			
Female	3	5	29
Male	5	3	30
Children's Depression Ratings Scale-Revised (CDRS-R) total score			
CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms.			
Units: scores on a scale			

arithmetic mean	57.88	48.63	
standard deviation	± 9.19	± 6.25	-

## End points

### End points reporting groups

Reporting group title	Desvenlafaxine 10 mg Children
Reporting group description: Desvenlafaxine sustained release 10 mg tablet.	
Reporting group title	Desvenlafaxine 25 mg Children
Reporting group description: Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
Reporting group title	Desvenlafaxine 50 mg Children
Reporting group description: Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 100 mg Children
Reporting group description: Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 25 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.	
Reporting group title	Desvenlafaxine 50 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 100 mg Adolescent
Reporting group description: Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.	
Reporting group title	Desvenlafaxine 200 mg Adolescent
Reporting group description: Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14.	
Subject analysis set title	Desvenlafaxine – Combined Children Cohorts
Subject analysis set type	Safety analysis
Subject analysis set description: Desvenlafaxine sustained release tablets for 10 mg, 25 mg, 50 mg, and 100 mg children cohort dose levels.	
Subject analysis set title	Desvenlafaxine – Combined Adolescent Cohorts
Subject analysis set type	Safety analysis
Subject analysis set description: Desvenlafaxine sustained release tablets for 25 mg, 50 mg, 100 mg, and 200 mg adolescent cohort dose levels.	
Subject analysis set title	Desvenlafaxine - Combined Children and Adolescent Cohorts
Subject analysis set type	Safety analysis
Subject analysis set description: Desvenlafaxine sustained release tablets for 10 mg, 25 mg, 50 mg, and 100 mg children cohort dose levels and Desvenlafaxine sustained release tablets for 25 mg, 50 mg, 100 mg, and 200 mg adolescent cohort dose levels.	

**Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)**

End point title	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) <sup>[1]</sup>
-----------------	---

End point description:

AEs are any untoward, undesired, or unplanned event in the form of signs, symptoms, disease, or laboratory or physiologic observations occurring in a person given study treatment. The event does not need to be causally related to the study treatment. SAEs are adverse events that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability or incapacity, result in cancer, or result in a congenital anomaly or birth defect. Safety population includes all treatment-assigned subjects who have taken at least 1 dose of study treatment.

End point type	Primary
----------------	---------

End point timeframe:

Baseline to Follow-up (up to Day 77)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported.

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: subjects				
Serious Adverse Events	0	0	0	0
Non-serious Adverse Events	1	3	3	7

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: subjects				
Serious Adverse Events	1	0	0	0
Non-serious Adverse Events	4	2	7	7

**Statistical analyses**

No statistical analyses for this end point

**Primary: Maximum Observed Plasma Concentration (C<sub>max</sub>)**

End point title	Maximum Observed Plasma Concentration (C <sub>max</sub> ) <sup>[2]</sup>
-----------------	--

End point description:

Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms per milliliter (ng/mL). PK population: all subjects in the Safety population with available plasma concentration data from both the inpatient and outpatient phases of the study that are properly identified with respect to dosing and sampling times.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported.

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: ng/mL				
arithmetic mean (standard deviation)	33.9 (± 12.1)	98 (± 60.5)	108 (± 27)	263 (± 66)

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: ng/mL				
arithmetic mean (standard deviation)	46.1 (± 15.9)	93.9 (± 15.5)	202 (± 92)	449 (± 126)

## Statistical analyses

No statistical analyses for this end point

## Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax)

End point title	Time to Reach Maximum Observed Plasma Concentration (Tmax) <sup>[3]</sup>
-----------------	---

End point description:

Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hours (hr). PK population: all subjects in the safety population with available plasma concentration data from both the inpatient and outpatient phases of the study that are properly identified with respect to dosing and sampling times.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported.

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: hr				
arithmetic mean (standard deviation)	4.7 (± 2.1)	4.3 (± 1.4)	5.1 (± 3)	5 (± 2)

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: hr				
arithmetic mean (standard deviation)	4.3 (± 0.7)	8.7 (± 7.1)	7.6 (± 3.4)	7.5 (± 4.1)

## Statistical analyses

No statistical analyses for this end point

### Primary: Plasma Decay Half-Life (t<sub>1/2</sub>)

End point title	Plasma Decay Half-Life (t <sub>1/2</sub> ) <sup>[4]</sup>
-----------------	---

End point description:

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as hr. PK population: all subjects in the safety population with available plasma concentration data from both the inpatient and outpatient phases of the study that are properly identified with respect to dosing and sampling times.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported.

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: hr				
arithmetic mean (standard deviation)	7.8 (± 1.4)	8.6 (± 1.6)	9.4 (± 2.7)	9 (± 2)

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
------------------	---------------------------------------	---------------------------------------	--	--

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: hr				
arithmetic mean (standard deviation)	12 (± 3)	10.2 (± 3.7)	9.6 (± 2)	9.8 (± 2.7)

## Statistical analyses

No statistical analyses for this end point

### Primary: Area Under the Curve From Time Zero to Infinity (AUC<sub>0-∞</sub>)

End point title	Area Under the Curve From Time Zero to Infinity (AUC <sub>0-∞</sub> ) <sup>[5]</sup>
-----------------	--

End point description:

AUC (0-∞) = Area under the plasma concentration versus time curve from time zero (pre-dose) to infinity. Noncompartmental PK parameter obtained using 0 to 72 hour concentration data from venous blood samples measured as nanograms multiplied by hours divided by milliliters (ng\*hr/mL). PK population: all subjects in the safety population with available plasma concentration data from both the inpatient and outpatient phases of the study that are properly identified with respect to dosing and sampling times.

End point type	Primary
----------------	---------

End point timeframe:

Pre-dose (0 hour) and Post-dose (0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, and 72 hours) on Days 28 and 56

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive data was planned to be reported.

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: ng*hr/mL				
arithmetic mean (standard deviation)	628 (± 346)	1704 (± 553)	2414 (± 924)	6732 (± 3031)

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: ng*hr/mL				
arithmetic mean (standard deviation)	1123 (± 361)	2281 (± 689)	5290 (± 2188)	11730 (± 3113)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Population Pharmacokinetics Dose Normalized AUC (AUC/D): First Method, Second Method

End point title	Population Pharmacokinetics Dose Normalized AUC (AUC/D): First Method, Second Method
-----------------	--

### End point description:

Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation  $Y=A*W^b$  ( $Y=AUC/D$ ;  $A$ =coefficient;  $W$ =variable;  $b$ =exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose ( $[ng*hr/mL]/mg$  of dose). PK population; data was insufficient to examine the effect of age, sex, ethnicity, and food on the PK of desvenlafaxine. Coefficient and exponent values were calculated for variable of body weight, however, the AUC/D values were not summarized as descriptive statistics.

End point type	Secondary
----------------	-----------

### End point timeframe:

Day 1, Day 28, and Day 56

End point values	Desvenlafaxine – Combined Children Cohorts	Desvenlafaxine – Combined Adolescent Cohorts		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>		
Units: ng*hr/mL/mg of dose				
arithmetic mean (standard deviation)	()	()		

### Notes:

[6] - AUC/D values were not summarized as descriptive statistics.

[7] - AUC/D values were not summarized as descriptive statistics.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Population Pharmacokinetics Dose Normalized AUC (AUC/D): Third Method

End point title	Population Pharmacokinetics Dose Normalized AUC (AUC/D): Third Method
-----------------	---

### End point description:

Relationship of variables (i.e., age, sex, ethnicity, and food) examined by fitting dose normalized AUC (AUC/D) values to a power model. AUC/D regressed against variables using power equation  $Y=A*W^b$  ( $Y=AUC/D$ ;  $A$ =coefficient;  $W$ =variable;  $b$ =exponent). AUC values from children cohort (ages 7 to 11) combined doses=first method of analysis. AUC from adolescent cohort (ages 12 to 17) combined doses=second method of analysis. AUC values combined from both cohorts=third method of analysis. Measured as nanograms multiplied by hours divided by milliliters per milligram of dose ( $[ng*hr/mL]/mg$  of dose). PK population; data was insufficient to examine the effect of age, sex, ethnicity, and food on the PK of desvenlafaxine. Coefficient and exponent values were calculated for variable of body weight, however, the AUC/D values were not summarized as descriptive statistics.

End point type	Secondary
----------------	-----------

### End point timeframe:

Day 1, Day 28, and Day 56



<b>End point values</b>	Desvenlafaxine - Combined Children and Adolescent Cohorts			
Subject group type	Subject analysis set			
Number of subjects analysed	0 <sup>[8]</sup>			
Units: ng*hr/mL/mg of dose				
arithmetic mean (standard deviation)	( )			

Notes:

[8] - AUC/D values were not summarized as descriptive statistics.

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score

End point title	Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score
-----------------	--

End point description:

CDRS-R total score: scale measures 17 depressive symptoms, of which 3 are rated 1 to 5 and 14 are rated 1 to 7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17 to 113. Lower total scores indicate lower intensity of symptoms. Intent To Treat (ITT): all treatment-assigned subjects with a baseline primary efficacy evaluation, at least 1 dose of study treatment, and at least 1 primary efficacy evaluation after the first dose of study treatment.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)

<b>End point values</b>	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: scores on a scale				
arithmetic mean (standard deviation)				
Inpatient Days 1 to 4	-6.83 (± 6.15)	-9.86 (± 5.4)	-2.78 (± 3.07)	-6.43 (± 10)
Outpatient Days 5 to 7	-10.67 (± 6.44)	-13.86 (± 8.51)	-10.44 (± 10.79)	-7.86 (± 8.28)
Outpatient Week 2	-17.67 (± 6.92)	-18.86 (± 10.51)	-14.44 (± 12.68)	-9.57 (± 10.83)
Outpatient Week 3	-19.67 (± 6.77)	-18.57 (± 7.93)	-16.89 (± 13.49)	-10.43 (± 9.11)
Outpatient Week 4	-19.5 (± 6.5)	-20.86 (± 10.98)	-17.56 (± 15.99)	-10 (± 4.69)
Outpatient Week 5	-19.5 (± 6.5)	-23 (± 8.56)	-19.56 (± 13.46)	-10.29 (± 4.39)
Outpatient Week 6	-21.83 (± 6.77)	-19.86 (± 9.94)	-18.44 (± 13.79)	-12 (± 5.48)
Outpatient Week 7	-21.83 (± 6.77)	-20.43 (± 10.06)	-19.11 (± 13.2)	-12 (± 5.48)
Outpatient Week 8	-22 (± 7.01)	-20.29 (± 7.18)	-19.78 (± 14.49)	-14.14 (± 6.52)

Outpatient Week >8	-22 (± 7.01)	-20 (± 7.05)	19.89 (± 14.51)	-14.14 (± 6.52)
--------------------	--------------	--------------	-----------------	-----------------

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: scores on a scale				
arithmetic mean (standard deviation)				
Inpatient Days 1 to 4	-7 (± 18.18)	-4.57 (± 2.99)	-8.25 (± 4.33)	-10.38 (± 13.45)
Outpatient Days 5 to 7	-8 (± 13.88)	-8.29 (± 4.27)	-9.5 (± 8.11)	-11.25 (± 14)
Outpatient Week 2	-8.29 (± 13.46)	-11.29 (± 5.53)	-18.13 (± 11.12)	-13.13 (± 14.88)
Outpatient Week 3	-11.71 (± 13.23)	-14.57 (± 6.19)	-21.25 (± 10.99)	-13.13 (± 11.47)
Outpatient Week 4	-14.57 (± 14.06)	-19.43 (± 9.43)	-23.5 (± 10.69)	-12.5 (± 9.41)
Outpatient Week 5	-14.57 (± 14.06)	-19.43 (± 9.43)	-23.88 (± 10.36)	-12.5 (± 9.41)
Outpatient Week 6	-20.57 (± 18.98)	-17.14 (± 6.2)	-24.63 (± 8.99)	-14.38 (± 9.93)
Outpatient Week 7	-20.57 (± 18.98)	-17.14 (± 6.2)	-25.38 (± 7.87)	-14.5 (± 9.89)
Outpatient Week 8	-21.43 (± 19.86)	-22.29 (± 3.09)	-27.25 (± 6.78)	-15.38 (± 8.65)
Outpatient Week >8	-21.43 (± 19.86)	-22.29 (± 3.09)	-26.75 (± 7.42)	-15.38 (± 8.65)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAM-D17) Total Score

End point title	Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAM-D17) Total Score
-----------------	--

End point description:

HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, & weight loss). Total score ranges from 0 to 52; higher scores reflect higher severity of current illness states. ITT: all treatment-assigned subjects with a baseline primary efficacy evaluation, at least 1 dose of study treatment, and at least 1 primary efficacy evaluation after the first dose of study treatment.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: score on a scale				
arithmetic mean (standard deviation)				
Inpatient Days 1 to 4	-6 (± 5.73)	-5.43 (± 4.31)	-0.33 (± 1.94)	-2.43 (± 6.92)
Outpatient Days 5 to 7	-6 (± 5.73)	-5.43 (± 4.31)	-0.33 (± 1.94)	-2.43 (± 6.92)
Outpatient Week 2	-9.33 (± 7)	-10.71 (± 4.61)	-6.11 (± 2.67)	-5.57 (± 4.2)
Outpatient Week 3	-9.33 (± 7)	-10.29 (± 5.41)	-6.11 (± 2.67)	-5.57 (± 4.2)
Outpatient Week 4	-11 (± 5.62)	-13 (± 6.3)	-7.22 (± 5.61)	-7.57 (± 3.05)
Outpatient Week 5	-11 (± 5.62)	-14.14 (± 4.1)	-7.56 (± 5.64)	-9 (± 1.91)
Outpatient Week 8	-12.17 (± 6.01)	-14 (± 4.62)	-8.44 (± 6.88)	-11.14 (± 4.14)
Outpatient Week >8	-12.17 (± 6.01)	-13.86 (± 4.81)	-9.11 (± 6.68)	-11.14 (± 4.14)

End point values	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: score on a scale				
arithmetic mean (standard deviation)				
Inpatient Days 1 to 4	-2.29 (± 7.45)	-0.57 (± 1.13)	-1.5 (± 4.54)	-5.63 (± 7.42)
Outpatient Days 5 to 7	-2 (± 7.59)	-0.57 (± 1.13)	-1.5 (± 4.54)	-5.63 (± 7.42)
Outpatient Week 2	-2.71 (± 4.27)	-5.71 (± 3.4)	-8.13 (± 4.91)	-9.38 (± 7.41)
Outpatient Week 3	-2.71 (± 4.27)	-5.71 (± 3.4)	-8.13 (± 4.91)	-8.88 (± 6.33)
Outpatient Week 4	-7.29 (± 5.19)	-7.57 (± 2.99)	-12.13 (± 5.69)	-9 (± 5.24)
Outpatient Week 5	-7.29 (± 5.19)	-7.57 (± 2.99)	-12.25 (± 5.73)	-9 (± 5.24)
Outpatient Week 8	-11.14 (± 9.56)	-9.86 (± 3.93)	-14.25 (± 3.96)	-11.63 (± 5.4)
Outpatient Week >8	-11.14 (± 9.56)	-9.86 (± 3.93)	-13 (± 5.37)	-11.63 (± 5.4)

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percentage of Subjects With a Categorical Clinical Global Impressions Scale- Severity (CGI-S) Score at Every Visit

End point title	Percentage of Subjects With a Categorical Clinical Global Impressions Scale- Severity (CGI-S) Score at Every Visit
-----------------	--

End point description:

CGI-S: 7-point clinician rated scale to assess severity of subjects current illness state; range: 1=normal, not ill at all, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill,

6=severely ill, 7=among the most extremely ill patients. Higher scores reflect higher severity of current illness states. ITT; no subjects had a CGI-S score of 6 or 7, therefore only scores 1 through 5 are reported.

End point type	Other pre-specified
End point timeframe:	
Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)	

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: percentage of subjects				
number (not applicable)				
Inpatient Days 1 to 4: not ill at all	0	0	0	0
Inpatient Days 1 to 4: borderline ill	0	0	0	0
Inpatient Days 1 to 4: mildly ill	0	0	0	14.3
Inpatient Days 1 to 4: moderately ill	100	100	88.9	85.7
Inpatient Days 1 to 4: markedly ill	0	0	11.1	0
Outpatient Days 5 to 7: not ill at all	0	0	0	0
Outpatient Days 5 to 7: borderline ill	0	0	0	0
Outpatient Days 5 to 7: mildly ill	0	42.9	44.4	0
Outpatient Days 5 to 7: moderately ill	100	57.1	55.6	100
Outpatient Days 5 to 7: markedly ill	0	0	0	0
Outpatient Week 2: not ill at all	0	0	0	0
Outpatient Week 2: borderline ill	0	14.3	11.1	0
Outpatient Week 2: mildly ill	66.7	57.1	55.6	0
Outpatient Week 2: moderately ill	33.3	28.6	33.3	100
Outpatient Week 2: markedly ill	0	0	0	0
Outpatient Week 3: not ill at all	0	0	0	0
Outpatient Week 3: borderline ill	0	57.1	0	0
Outpatient Week 3: mildly ill	66.7	42.9	88.9	0
Outpatient Week 3: moderately ill	33.3	0	11.1	100
Outpatient Week 3: markedly ill	0	0	0	0
Outpatient Week 4: not ill at all	0	14.3	0	0
Outpatient Week 4: borderline ill	16.7	57.1	11.1	0
Outpatient Week 4: mildly ill	66.7	28.6	66.7	14.3
Outpatient Week 4: moderately ill	16.7	0	22.2	85.7
Outpatient Week 4: markedly ill	0	0	0	0
Outpatient Week 5: not ill at all	0	14.3	11.1	0
Outpatient Week 5: borderline ill	16.7	57.1	11.1	0
Outpatient Week 5: mildly ill	66.7	28.6	55.6	14.3
Outpatient Week 5: moderately ill	16.7	0	22.2	85.7
Outpatient Week 5: markedly ill	0	0	0	0
Outpatient Week 6: not ill at all	0	0	11.1	0
Outpatient Week 6: borderline ill	50	57.1	11.1	0
Outpatient Week 6: mildly ill	50	42.9	66.7	28.6
Outpatient Week 6: moderately ill	0	0	11.1	71.4
Outpatient Week 6: markedly ill	0	0	0	0

Outpatient Week 7: not ill at all	0	0	11.1	0
Outpatient Week 7: borderline ill	50	42.9	11.1	0
Outpatient Week 7: mildly ill	50	57.1	77.8	28.6
Outpatient Week 7: moderately ill	0	0	0	71.4
Outpatient Week 7: markedly ill	0	0	0	0
Outpatient Week 8: not ill at all	0	0	11.1	0
Outpatient Week 8: borderline ill	66.7	42.9	22.2	0
Outpatient Week 8: mildly ill	33.3	57.1	66.7	71.4
Outpatient Week 8: moderately ill	0	0	0	28.6
Outpatient Week 8: markedly ill	0	0	0	0
Outpatient Week >8: not ill at all	0	0	11.1	0
Outpatient Week >8: borderline ill	66.7	57.1	33.3	0
Outpatient Week >8: mildly ill	33.3	42.9	55.6	71.4
Outpatient Week >8: moderately ill	0	0	0	28.6
Outpatient Week >8: markedly ill	0	0	0	0

<b>End point values</b>	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: percentage of subjects				
number (not applicable)				
Inpatient Days 1 to 4: not ill at all	0	0	0	0
Inpatient Days 1 to 4: borderline ill	0	0	0	0
Inpatient Days 1 to 4: mildly ill	0	0	0	12.5
Inpatient Days 1 to 4: moderately ill	100	100	100	87.5
Inpatient Days 1 to 4: markedly ill	0	0	0	0
Outpatient Days 5 to 7: not ill at all	0	0	0	0
Outpatient Days 5 to 7: borderline ill	0	0	0	0
Outpatient Days 5 to 7: mildly ill	0	14.3	0	12.5
Outpatient Days 5 to 7: moderately ill	100	85.7	100	87.5
Outpatient Days 5 to 7: markedly ill	0	0	0	0
Outpatient Week 2: not ill at all	0	0	0	0
Outpatient Week 2: borderline ill	0	0	0	0
Outpatient Week 2: mildly ill	0	28.6	50	12.5
Outpatient Week 2: moderately ill	100	71.4	50	87.5
Outpatient Week 2: markedly ill	0	0	0	0
Outpatient Week 3: not ill at all	0	0	0	0
Outpatient Week 3: borderline ill	0	0	25	0
Outpatient Week 3: mildly ill	28.6	57.1	37.5	12.5
Outpatient Week 3: moderately ill	71.4	42.9	37.5	87.5
Outpatient Week 3: markedly ill	0	0	0	0
Outpatient Week 4: not ill at all	0	0	0	0
Outpatient Week 4: borderline ill	0	0	50	0
Outpatient Week 4: mildly ill	28.6	85.7	12.5	37.5
Outpatient Week 4: moderately ill	71.4	14.3	37.5	62.5
Outpatient Week 4: markedly ill	0	0	0	0
Outpatient Week 5: not ill at all	0	0	0	0
Outpatient Week 5: borderline ill	0	0	50	0

Outpatient Week 5: mildly ill	28.6	85.7	12.5	37.5
Outpatient Week 5: moderately ill	71.4	14.3	37.5	62.5
Outpatient Week 5: markedly ill	0	0	0	0
Outpatient Week 6: not ill at all	0	0	0	0
Outpatient Week 6: borderline ill	0	14.3	62.5	0
Outpatient Week 6: mildly ill	57.1	57.1	12.5	50
Outpatient Week 6: moderately ill	42.9	28.6	25	50
Outpatient Week 6: markedly ill	0	0	0	0
Outpatient Week 7: not ill at all	0	0	0	0
Outpatient Week 7: borderline ill	0	14.3	62.5	0
Outpatient Week 7: mildly ill	57.1	57.1	25	50
Outpatient Week 7: moderately ill	42.9	28.6	12.5	50
Outpatient Week 7: markedly ill	0	0	0	0
Outpatient Week 8: not ill at all	0	0	12.5	0
Outpatient Week 8: borderline ill	0	28.6	50	0
Outpatient Week 8: mildly ill	57.1	71.4	25	62.5
Outpatient Week 8: moderately ill	42.9	0	12.5	37.5
Outpatient Week 8: markedly ill	0	0	0	0
Outpatient Week >8: not ill at all	0	0	12.5	0
Outpatient Week >8: borderline ill	0	28.6	50	0
Outpatient Week >8: mildly ill	57.1	71.4	25	62.5
Outpatient Week >8: moderately ill	42.9	0	12.5	37.5
Outpatient Week >8: markedly ill	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percentage of Subjects With a Categorical Clinical Global Impressions Scale- Improvement (CGI-I) Score at Every Visit

End point title	Percentage of Subjects With a Categorical Clinical Global Impressions Scale- Improvement (CGI-I) Score at Every Visit
-----------------	---

End point description:

CGI-I: 7-point clinician rated scale ranging from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, to 7=very much worse. Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Scores above 4 reflect worsening of illness state as compared to baseline. ITT; no subjects had a CGI-I score of 6 or 7, therefore only scores 1 through 5 are reported.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline, Inpatient Days 1 to 4, Outpatient Days 5 to 7, Outpatient Weeks 2 through 8 and Outpatient Week >8 (or early termination)

End point values	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children	Desvenlafaxine 100 mg Children
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	7	9	7
Units: percentage of subjects				
number (not applicable)				
Inpatient Days 1 to 4: very much improved	0	0	0	0
Inpatient Days 1 to 4: much improved	0	0	0	14.3
Inpatient Days 1 to 4: minimally improved	0	0	11.1	0
Inpatient Days 1 to 4: no change	100	100	88.9	85.7
Inpatient Days 1 to 4: minimally worse	0	0	0	0
Outpatient Days 5 to 7: very much improved	0	0	0	0
Outpatient Days 5 to 7: much improved	0	14.3	11.1	0
Outpatient Days 5 to 7: minimally improved	50	14.3	55.6	42.9
Outpatient Days 5 to 7: no change	50	71.4	33.3	57.1
Outpatient Days 5 to 7: minimally worse	0	0	0	0
Outpatient Week 2: very much improved	0	0	11.1	0
Outpatient Week 2: much improved	33.3	28.6	44.4	14.3
Outpatient Week 2: minimally improved	50	42.9	11.1	42.9
Outpatient Week 2: no change	16.7	28.6	33.3	42.9
Outpatient Week 2: minimally worse	0	0	0	0
Outpatient Week 3: very much improved	0	0	0	0
Outpatient Week 3: much improved	50	85.7	44.4	14.3
Outpatient Week 3: minimally improved	50	14.3	44.4	57.1
Outpatient Week 3: no change	0	0	11.1	28.6
Outpatient Week 3: minimally worse	0	0	0	0
Outpatient Week 4: very much improved	0	14.3	0	0
Outpatient Week 4: much improved	50	71.4	55.6	28.6
Outpatient Week 4: minimally improved	50	14.3	22.2	57.1
Outpatient Week 4: no change	0	0	11.1	14.3
Outpatient Week 4: minimally worse	0	0	11.1	0
Outpatient Week 5: very much improved	0	14.3	11.1	0
Outpatient Week 5: much improved	50	85.7	55.6	28.6
Outpatient Week 5: minimally improved	50	0	22.2	71.4
Outpatient Week 5: no change	0	0	0	0
Outpatient Week 5: minimally worse	0	0	11.1	0
Outpatient Week 6: very much improved	0	14.3	11.1	0
Outpatient Week 6: much improved	50	57.1	66.7	28.6
Outpatient Week 6: minimally improved	50	28.6	22.2	71.4
Outpatient Week 6: no change	0	0	0	0
Outpatient Week 6: minimally worse	0	0	0	0
Outpatient Week 7: very much improved	0	14.3	11.1	0
Outpatient Week 7: much improved	50	42.9	55.6	28.6
Outpatient Week 7: minimally improved	50	42.9	33.3	71.4
Outpatient Week 7: no change	0	0	0	0

Outpatient Week 7: minimally worse	0	0	0	0
Outpatient Week 8: very much improved	0	14.3	22.2	0
Outpatient Week 8: much improved	83.3	71.4	22.2	71.4
Outpatient Week 8: minimally improved	16.7	14.3	55.6	28.6
Outpatient Week 8: no change	0	0	0	0
Outpatient Week 8: minimally worse	0	0	0	0
Outpatient Week >8: very much improved	0	14.3	22.2	0
Outpatient Week >8: much improved	83.3	71.4	33.3	71.4
Outpatient Week >8: minimally improved	16.7	14.3	44.4	28.6
Outpatient Week >8: no change	0	0	0	0
Outpatient Week >8: minimally worse	0	0	0	0

<b>End point values</b>	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	8	8
Units: percentage of subjects				
number (not applicable)				
Inpatient Days 1 to 4: very much improved	0	0	0	0
Inpatient Days 1 to 4: much improved	14.3	0	0	12.5
Inpatient Days 1 to 4: minimally improved	0	0	12.5	37.5
Inpatient Days 1 to 4: no change	85.7	100	87.5	50
Inpatient Days 1 to 4: minimally worse	0	0	0	0
Outpatient Days 5 to 7: very much improved	0	0	0	0
Outpatient Days 5 to 7: much improved	0	0	0	12.5
Outpatient Days 5 to 7: minimally improved	42.9	57.1	25	25
Outpatient Days 5 to 7: no change	57.1	42.9	75	62.5
Outpatient Days 5 to 7: minimally worse	0	0	0	0
Outpatient Week 2: very much improved	0	0	0	0
Outpatient Week 2: much improved	0	0	0	25
Outpatient Week 2: minimally improved	42.9	57.1	75	50
Outpatient Week 2: no change	57.1	42.9	25	25
Outpatient Week 2: minimally worse	0	0	0	0
Outpatient Week 3: very much improved	0	0	0	0
Outpatient Week 3: much improved	28.6	0	37.5	25
Outpatient Week 3: minimally improved	57.1	71.4	37.5	62.5
Outpatient Week 3: no change	14.3	28.6	25	12.5
Outpatient Week 3: minimally worse	0	0	0	0
Outpatient Week 4: very much improved	0	0	0	0
Outpatient Week 4: much improved	28.6	0	50	37.5
Outpatient Week 4: minimally improved	57.1	85.7	37.5	37.5
Outpatient Week 4: no change	14.3	14.3	12.5	12.5



Outpatient Week 4: minimally worse	0	0	0	12.5
Outpatient Week 5: very much improved	0	0	0	0
Outpatient Week 5: much improved	28.6	0	50	37.5
Outpatient Week 5: minimally improved	57.1	85.7	37.5	37.5
Outpatient Week 5: no change	14.3	14.3	12.5	12.5
Outpatient Week 5: minimally worse	0	0	0	12.5
Outpatient Week 6: very much improved	0	0	0	0
Outpatient Week 6: much improved	57.1	71.4	75	50
Outpatient Week 6: minimally improved	28.6	28.6	12.5	25
Outpatient Week 6: no change	14.3	0	12.5	25
Outpatient Week 6: minimally worse	0	0	0	0
Outpatient Week 7: very much improved	0	0	0	0
Outpatient Week 7: much improved	57.1	71.4	75	50
Outpatient Week 7: minimally improved	28.6	28.6	12.5	37.5
Outpatient Week 7: no change	14.3	0	12.5	12.5
Outpatient Week 7: minimally worse	0	0	0	0
Outpatient Week 8: very much improved	0	0	12.5	0
Outpatient Week 8: much improved	57.1	71.4	75	62.5
Outpatient Week 8: minimally improved	28.6	28.6	0	37.5
Outpatient Week 8: no change	14.3	0	12.5	0
Outpatient Week 8: minimally worse	0	0	0	0
Outpatient Week >8: very much improved	0	0	12.5	0
Outpatient Week >8: much improved	57.1	71.4	75	62.5
Outpatient Week >8: minimally improved	28.6	28.6	0	37.5
Outpatient Week >8: no change	14.3	0	12.5	0
Outpatient Week >8: minimally worse	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to Day 77

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as non-serious in another, or 1 subject may have experienced both serious, non-serious event during study. EU BR specific AE tables were generated separately as per EU format using latest coding.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	Desvenlafaxine 10 mg Children
-----------------------	-------------------------------

Reporting group description:

Desvenlafaxine sustained release 10 milligram (mg) tablet.

Reporting group title	Desvenlafaxine 25 mg Children
-----------------------	-------------------------------

Reporting group description:

Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.

Reporting group title	Desvenlafaxine 50 mg Children
-----------------------	-------------------------------

Reporting group description:

Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.

Reporting group title	Desvenlafaxine 100 mg Children
-----------------------	--------------------------------

Reporting group description:

Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.

Reporting group title	Desvenlafaxine 25 mg Adolescent
-----------------------	---------------------------------

Reporting group description:

Desvenlafaxine sustained release 25 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 56, 10 mg tablet for 7 day taper.

Reporting group title	Desvenlafaxine 50 mg Adolescent
-----------------------	---------------------------------

Reporting group description:

Desvenlafaxine sustained release 50 mg tablet on Day 1, 10 mg tablet on Days 4 through 7, 25 mg tablet on Days 8 through 14, 50 mg tablet on days 15 through 56, 25 mg tablet on taper Days 1 through 7, 10 mg tablet for taper Days 8 through 14.

Reporting group title	Desvenlafaxine 100 mg Adolescent
-----------------------	----------------------------------

Reporting group description:

Desvenlafaxine sustained release 100 mg tablet on Day 1, 25 mg tablet on Days 4 through 7, 50 mg tablet on Days 8 through 14, 100 mg tablet on days 15 through 56, 50 mg tablet on taper Days 1 through 7, 25 mg tablet for taper Days 8 through 14.

Reporting group title	Desvenlafaxine 200 mg Adolescent
-----------------------	----------------------------------

Reporting group description:

Desvenlafaxine sustained release two 100 mg tablets on Day 1, 50 mg tablet on Days 4 through 7, 100 mg tablet on Days 8 through 14, two 100 mg tablets on days 15 through 56, 100 mg tablet on taper Days 1 through 7, 50 mg tablet for taper Days 8 through 14.

<b>Serious adverse events</b>	Desvenlafaxine 10 mg Children	Desvenlafaxine 25 mg Children	Desvenlafaxine 50 mg Children
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Psychiatric disorders			
Suicidal behaviour			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Desvenlafaxine 100 mg Children	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Psychiatric disorders			
Suicidal behaviour			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	0 / 8 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Psychiatric disorders			
Suicidal behaviour			
subjects affected / exposed	0 / 8 (0.00%)	0 / 8 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	<b>Desvenlafaxine 10 mg Children</b>	<b>Desvenlafaxine 25 mg Children</b>	<b>Desvenlafaxine 50 mg Children</b>
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)	3 / 7 (42.86%)	3 / 9 (33.33%)
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Feeling jittery			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Infusion site extravasation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 7 (14.29%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Sinus congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 7 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract congestion			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Epistaxis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Psychiatric disorders Affect lability subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Investigations Heart rate increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1	0 / 9 (0.00%) 0
Injury, poisoning and procedural complications Intentional overdose subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 7 (0.00%) 0	1 / 9 (11.11%) 6

Somnolence subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 9 (11.11%) 2
Nerve compression subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 9 (11.11%) 1
Ocular hyperaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 7 (14.29%) 1	2 / 9 (22.22%) 2
Constipation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 9 (11.11%) 1
Vomiting subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	1 / 9 (11.11%) 2
Diarrhoea subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Faeces discoloured subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Skin and subcutaneous tissue disorders Blister subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Rash			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Skin irritation subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Infections and infestations Gastroenteritis viral subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Infectious mononucleosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 7 (0.00%) 0	0 / 9 (0.00%) 0

<b>Non-serious adverse events</b>	Desvenlafaxine 100 mg Children	Desvenlafaxine 25 mg Adolescent	Desvenlafaxine 50 mg Adolescent
Total subjects affected by non-serious adverse events subjects affected / exposed	7 / 7 (100.00%)	4 / 7 (57.14%)	2 / 7 (28.57%)
General disorders and administration site conditions Asthenia			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Feeling jittery subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Infusion site extravasation subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 3	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 4	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Sinus congestion subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Upper respiratory tract congestion subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Asthma subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Epistaxis			



subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Psychiatric disorders			
Affect lability			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
Depression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Investigations			
Heart rate increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Intentional overdose			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Headache			
subjects affected / exposed	3 / 7 (42.86%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	3	2	2
Somnolence			
subjects affected / exposed	1 / 7 (14.29%)	2 / 7 (28.57%)	1 / 7 (14.29%)
occurrences (all)	3	4	1
Nerve compression			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

Eye disorders			
Vision blurred			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	2 / 7 (28.57%)	2 / 7 (28.57%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Constipation			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Nausea			
subjects affected / exposed	2 / 7 (28.57%)	1 / 7 (14.29%)	1 / 7 (14.29%)
occurrences (all)	4	1	2
Vomiting			
subjects affected / exposed	2 / 7 (28.57%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	5	0	0
Diarrhoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Faeces discoloured			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Rash			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 7 (0.00%)
occurrences (all)	0	3	0
Skin irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Gastroenteritis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Desvenlafaxine 100 mg Adolescent	Desvenlafaxine 200 mg Adolescent	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 8 (87.50%)	8 / 8 (100.00%)	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 8 (12.50%)	
occurrences (all)	0	1	
Feeling jittery			
subjects affected / exposed	1 / 8 (12.50%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Infusion site extravasation			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 8 (12.50%) 1	
Reproductive system and breast disorders Dysmenorrhoea subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 8 (12.50%) 1	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Nasal congestion subjects affected / exposed occurrences (all)  Oropharyngeal pain subjects affected / exposed occurrences (all)  Sinus congestion subjects affected / exposed occurrences (all)  Upper respiratory tract congestion subjects affected / exposed occurrences (all)  Asthma subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  1 / 8 (12.50%) 3  0 / 8 (0.00%) 0  1 / 8 (12.50%) 1  0 / 8 (0.00%) 0	0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  1 / 8 (12.50%) 1  0 / 8 (0.00%) 0  0 / 8 (0.00%) 1  1 / 8 (12.50%) 1	
Psychiatric disorders Affect lability subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0	

Depression subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2	0 / 8 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 4	0 / 8 (0.00%) 0	
Investigations Heart rate increased subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0	
Injury, poisoning and procedural complications Intentional overdose subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0	
Skin laceration subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Headache subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 2	1 / 8 (12.50%) 1	
Somnolence subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 3	4 / 8 (50.00%) 10	
Nerve compression subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Eye disorders Vision blurred subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	0 / 8 (0.00%) 0	
Ocular hyperaemia			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2	0 / 8 (0.00%) 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 8 (0.00%)	2 / 8 (25.00%)	
occurrences (all)	0	2	
Constipation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 8 (0.00%)	
occurrences (all)	0	0	
Nausea			
subjects affected / exposed	0 / 8 (0.00%)	5 / 8 (62.50%)	
occurrences (all)	0	8	
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	2 / 8 (25.00%)	
occurrences (all)	0	8	
Diarrhoea			
subjects affected / exposed	1 / 8 (12.50%)	1 / 8 (12.50%)	
occurrences (all)	1	1	
Faeces discoloured			
subjects affected / exposed	1 / 8 (12.50%)	0 / 8 (0.00%)	
occurrences (all)	2	0	
Skin and subcutaneous tissue disorders			
Blister			
subjects affected / exposed	0 / 8 (0.00%)	0 / 8 (0.00%)	
occurrences (all)	0	0	
Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 8 (0.00%)	
occurrences (all)	0	0	
Skin irritation			
subjects affected / exposed	1 / 8 (12.50%)	0 / 8 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 8 (0.00%)	
occurrences (all)	2	0	
Muscle spasms			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Infections and infestations			
Gastroenteritis viral subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0	
Gastrointestinal viral infection subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0	
Infectious mononucleosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 1	
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 8 (0.00%) 0	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 8 (12.50%) 2	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 May 2008	The Laboratory Determinations section was updated to reflect that additional UDS testing for known therapeutic drug(s) may be completed during the study, at the discretion of the investigator.
07 April 2009	The protocol was primarily updated to study 2 additional dose cohorts: 100 mg DVS SR in subjects in the child age stratum and 200 mg DVS SR in subjects in the adolescent age stratum. As a result of this change, dosing and test article information throughout the protocol has been updated. Additionally, the total number of planned subjects and study duration information were updated.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported